XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders’ Equity (Tables)
9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

 

   2024   2023   2024   2023 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2024   2023   2024   2023 
                 
Research and development  $58,168   $92,034   $171,033   $270,776 
General and administrative   49,726    66,056    138,432    229,951 
Total   $107,894   $158,090   $309,465   $500,727 
Schedule of Key Assumption of Fair Value of Stock Options Granted

For options granted during the nine months ended September 30, 2024 and 2023, the Company calculated the fair value of each option grant on the respective dates of grant using the following weighted average assumptions:

 

   2024   2023 
Expected term   5.76 years      5.73 years   
Risk-free interest rate   4.32%   3.73%
Expected dividend yield        
Expected volatility   97.78%   98.97%

Schedule of Stock Option Activity

A summary of stock option activity is as follows:

 

   Outstanding stock options 
   Number of shares   Weighted average exercise price 
Balance at December 31, 2023   262,247   $34.21 
Options granted   34,446    4.77 
Options exercised   -    - 
Options forfeited   -    - 
Options cancelled   (10,209)   142.99 
Balance at September 30, 2024   286,484    26.79 
           
Options exercisable at September 30, 2024   224,430    32.33 
Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable at September 30, 2024:

 

 Options outstanding    Options exercisable 
 Number outstanding    Weighted average remaining contractual life (Years)    Weighted average exercise
 price
    Aggregate
 intrinsic
 value
    Number exerciseable    Weighted average remaining contractual life (Years)    Weighted average exercise price    Aggregate intrinsic value 
                                      
 286,484    6.50   $26.79   $13,069    224,430    5.85   $32.33   $- 
Summary of Restricted Stock Unit Activity

A summary of restricted stock unit activity is as follows:

 

   Number of Unvested Restricted Stock Units 
Balance at December 31, 2023   - 
Granted   21,762 
Vested   - 
Cancelled   - 
Balance at September 30, 2024   21,762 
Schedule of Fair Value of Warrants

 

   September 30, 2024   December 31, 2023 
Expected life in years   0.13    0.88 
Risk-free interest rate   4.87%   4.79%
Dividend yield        
Volatility   107.82%   100.00%
Stock price  $4.49   $2.79 

Schedule of Reconciliation of Warrant Liability

 

   Warrant Liability 
Balance at December 31, 2023  $17,166 
Change in fair value of common stock warrants   (13,580)
Balance at September 30, 2024  $3,586 
Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price

The following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:

 

   Warrants   Weighted Average Exercise Price 
Outstanding at December 31, 2023   113,795   $8.72 
Issued   -    - 
Exercised   -    - 
Expired   -    - 
Cancelled   -    - 
Forfeited   -    - 
Balance at September 30, 2024   113,795   $8.72 
Schedule of Common Stock Warrants Outstanding

The following table summarizes information about common stock warrants outstanding at September 30, 2024:

 

Warrants outstanding
Number exercisable  Weighted average remaining contractual life (Years)   Weighted average exercise price   Aggregate intrinsic value 
                
113,795   0.25   $8.72   $-